Pilot, multicenter, randomized study on lopinavir/ritonavir-monotherapy vs lopinavir/ritonavir plus selected nucs [nucleosides], in HIV/HCV [hepatitis C virus] ARV [antiretroviral]-naive coinfected patients with chronic hepatitis C or compensated cirrhosis, starting treatment with ribavirin and pegylated interferon

Trial Profile

Pilot, multicenter, randomized study on lopinavir/ritonavir-monotherapy vs lopinavir/ritonavir plus selected nucs [nucleosides], in HIV/HCV [hepatitis C virus] ARV [antiretroviral]-naive coinfected patients with chronic hepatitis C or compensated cirrhosis, starting treatment with ribavirin and pegylated interferon

Recruiting
Phase of Trial: Phase III

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Lopinavir/ritonavir; Nucleosides; Peginterferon alfa-2a; Ribavirin
  • Indications Hepatitis C; HIV infections
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 07 Jun 2008 The expected completion date for this trial is now 1 Dec 2010, as reported by ClinicalTrials.gov.
    • 23 Mar 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top